BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 34066710)

  • 1. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.
    Ginghină O; Hudiță A; Zaharia C; Tsatsakis A; Mezhuev Y; Costache M; Gălățeanu B
    Materials (Basel); 2021 May; 14(9):. PubMed ID: 34066710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer.
    Rama AR; Jimenez-Lopez J; Cabeza L; Jimenez-Luna C; Leiva MC; Perazzoli G; Hernandez R; Zafra I; Ortiz R; Melguizo C; Prados J
    Curr Drug Deliv; 2016; 13(6):830-8. PubMed ID: 26634791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in nanomedicine preparative methods and their therapeutic potential for colorectal cancer: a critical review.
    Jain A; Bhattacharya S
    Front Oncol; 2023; 13():1211603. PubMed ID: 37427139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome technologies towards colorectal cancer therapeutics.
    Sang R; Stratton B; Engel A; Deng W
    Acta Biomater; 2021 Jun; 127():24-40. PubMed ID: 33812076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.
    Kasi PB; Mallela VR; Ambrozkiewicz F; Trailin A; Liška V; Hemminki K
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
    Si J; Zhao X; Gao S; Huang D; Sui M
    Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
    Zoetemelk M; Ramzy GM; Rausch M; Nowak-Sliwinska P
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32512790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
    Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
    Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line systemic therapy for metastatic colorectal cancer.
    Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basics to advances in nanotherapy of colorectal cancer.
    Tiwari A; Saraf S; Jain A; Panda PK; Verma A; Jain SK
    Drug Deliv Transl Res; 2020 Apr; 10(2):319-338. PubMed ID: 31701486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles: Attractive tools to treat colorectal cancer.
    Younis NK; Roumieh R; Bassil EP; Ghoubaira JA; Kobeissy F; Eid AH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1-13. PubMed ID: 36028154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.
    Choukaife H; Seyam S; Alallam B; Doolaanea AA; Alfatama M
    Int J Nanomedicine; 2022; 17():3933-3966. PubMed ID: 36105620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy.
    Wang W; Hao Y; Liu Y; Li R; Huang DB; Pan YY
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1654. PubMed ID: 32700465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research advances in nanomedicine applied to the systemic treatment of colorectal cancer.
    Yin L; Li H; Shi L; Chen K; Pan H; Han W
    Int J Cancer; 2023 Mar; 152(5):807-821. PubMed ID: 35984398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A shift in focus towards precision oncology, driven by revolutionary nanodiagnostics; revealing mysterious pathways in colorectal carcinogenesis.
    Sharma S; Bhattacharya S; Joshi K; Singh S
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16157-16177. PubMed ID: 37650995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.
    Ying K; Bai B; Gao X; Xu Y; Wang H; Xie B
    Front Bioeng Biotechnol; 2021; 9():670124. PubMed ID: 34307319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.